...
首页> 外文期刊>Contraception >Oral contraceptive use and cancer: Final report from the Oxford-Family Planning Association contraceptive study
【24h】

Oral contraceptive use and cancer: Final report from the Oxford-Family Planning Association contraceptive study

机译:口服避孕药的使用和癌症:牛津家庭计划协会避孕研究的最终报告

获取原文
获取原文并翻译 | 示例
           

摘要

Background This analysis provides the final results on cancer incidence in relation to oral contraceptive (OC) use from the Oxford-Family Planning Association (Oxford-FPA) contraceptive study, which closed at the end of 2010. An additional 6 years of observation have been added since our last report and there has been an increase in the numbers of cancers of over 50% at seven of the sites considered. Study Design The Oxford-FPA study includes 17032 women aged 25-39 years recruited from 1968 to 1974 at contraceptive clinics in England and Scotland. These women were using OCs, a diaphragm or an intrauterine device. Information about cancer incidence among them has been collected from recruitment until closure of the study. Results OC use was not related to nonreproductive cancer. Breast cancer findings (1087 cases) were entirely negative; the rate ratio (RR) comparing ever users of OCs with never users was 1.0 [95% confidence interval (CI): 0.9-1.1]. Only two cases of cervical cancer have been added since our last report (total: 61 cases); the RR comparing ever use with never use is now 3.4 (95% CI: 1.6-8.9). The risk of this disease increases sharply with duration of OC use and declines steadily with interval since last OC use. OC use protects against both uterine body cancer (124 cases) and ovarian cancer (143 cases). The RRs comparing ever use with never use were 0.5 (95% CI: 0.3-0.7) and 0.5 (95% CI: 0.4-0.7), respectively. Protection against both these cancers increased with duration of OC use and waned with interval since last use, but an effect was still present 28 or more years after discontinuation. Conclusions In our study, OC use had no effect on nonreproductive cancers or on breast cancer. The risk of cervical cancer was increased and that of uterine body cancer and ovarian cancer was decreased by OC use. All these effects increased with duration of use and declined with interval since last use. The beneficial effects of OC use on cancer outweighed the adverse effects. These findings should reassure older women who used OCs in the past.
机译:背景本分析提供了牛津家庭计划协会(Oxford-FPA)避孕研究中与口服避孕药(OC)使用相关的癌症发病率的最终结果,该研究于2010年底结束。已经进行了6年的观察。自上次报告以来,我们发现,在所考虑的七个地点,癌症的数量增加了50%以上。研究设计牛津FPA研究包括1968年至1974年在英格兰和苏格兰的避孕诊所招募的17032名25-39岁的女性。这些妇女正在使用OC,隔膜或宫内节育器。从招募到研究结束,已经收集了其中有关癌症发生率的信息。结果OC的使用与非生殖癌无关。乳腺癌结果(1087例)完全阴性;比较使用OC的用户和从未使用过的用户的比率(RR)为1.0 [95%置信区间(CI):0.9-1.1]。自上次报告以来,仅新增了2例宫颈癌(共61例);经常使用和不使用之间的RR现在为3.4(95%CI:1.6-8.9)。此病的风险随着使用OC的持续时间而急剧增加,并且自上一次使用OC以来的间隔随着时间而稳步下降。 OC的使用可以预防子宫体癌(124例)和卵巢癌(143例)。经常使用和不使用的RR分别为0.5(95%CI:0.3-0.7)和0.5(95%CI:0.4-0.7)。自从上次使用以来,针对这两种癌症的防护措施均随着使用OC的持续时间的增加而逐渐减弱,但在停药后28年或更长时间仍然有效。结论在我们的研究中,OC的使用对非生殖癌或乳腺癌没有影响。 OC的使用增加了子宫颈癌的风险,降低了子宫体癌和卵巢癌的风险。所有这些影响都随着使用时间的延长而增加,而自上次使用以来的间隔随着时间的推移而降低。 OC的使用对癌症的有益作用超过了不利影响。这些发现将使过去使用过OC的老年妇女放心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号